Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Molecular Characterization of Human Lymph Node Stromal Cells During the Earliest Phases of Rheumatoid Arthritis.

Karouzakis E, Hähnlein J, Grasso C, Semmelink JF, Tak PP, Gerlag DM, Gay S, Ospelt C, van Baarsen LGM.

Front Immunol. 2019 Aug 20;10:1863. doi: 10.3389/fimmu.2019.01863. eCollection 2019.

2.

Myeloid Dendritic Cells Are Enriched in Lymph Node Tissue of Early Rheumatoid Arthritis Patients but not in At Risk Individuals.

Ramwadhdoebe TH, Ramos MI, Maijer KI, van Lienden KP, Maas M, Gerlag DM, Tak PP, Lebre MC, van Baarsen LGM.

Cells. 2019 Jul 20;8(7). pii: E756. doi: 10.3390/cells8070756.

3.

BOB.1 controls memory B-cell fate in the germinal center reaction.

Levels MJ, Fehres CM, van Baarsen LGM, van Uden NOP, Germar K, O'Toole TG, Blijdorp ICJ, Semmelink JF, Doorenspleet ME, Bakker AQ, Krasavin M, Tomilin A, Brouard S, Spits H, Baeten DLP, Yeremenko NG.

J Autoimmun. 2019 Jul;101:131-144. doi: 10.1016/j.jaut.2019.04.011. Epub 2019 Apr 30.

4.

The cholesterol biosynthesis pathway regulates IL-10 expression in human Th1 cells.

Perucha E, Melchiotti R, Bibby JA, Wu W, Frederiksen KS, Roberts CA, Hall Z, LeFriec G, Robertson KA, Lavender P, Gerwien JG, Taams LS, Griffin JL, de Rinaldis E, van Baarsen LGM, Kemper C, Ghazal P, Cope AP.

Nat Commun. 2019 Jan 30;10(1):498. doi: 10.1038/s41467-019-08332-9.

5.

Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis.

Ramwadhdoebe TH, van Baarsen LGM, Boumans MJH, Bruijnen STG, Safy M, Berger FH, Semmelink JF, van der Laken CJ, Gerlag DM, Thurlings RM, Tak PP.

Rheumatology (Oxford). 2019 Jun 1;58(6):1075-1085. doi: 10.1093/rheumatology/key428.

6.

Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis.

Hähnlein JS, Nadafi R, de Jong T, Ramwadhdoebe TH, Semmelink JF, Maijer KI, Zijlstra IA, Maas M, Gerlag DM, Geijtenbeek TBH, Tak PP, Mebius RE, van Baarsen LGM.

Arthritis Res Ther. 2018 Feb 26;20(1):35. doi: 10.1186/s13075-018-1529-8.

7.

Distinctive expression of T cell guiding molecules in human autoimmune lymph node stromal cells upon TLR3 triggering.

Hähnlein JS, Ramwadhdoebe TH, Semmelink JF, Choi IY, Berger FH, Maas M, Gerlag DM, Tak PP, Geijtenbeek TBH, van Baarsen LGM.

Sci Rep. 2018 Jan 29;8(1):1736. doi: 10.1038/s41598-018-19951-5.

8.

Lymph node biopsy analysis reveals an altered immunoregulatory balance already during the at-risk phase of autoantibody positive rheumatoid arthritis.

Ramwadhdoebe TH, Hähnlein J, Maijer KI, van Boven LJ, Gerlag DM, Tak PP, van Baarsen LG.

Eur J Immunol. 2016 Dec;46(12):2812-2821. doi: 10.1002/eji.201646393. Epub 2016 Oct 12.

9.

Brief Report: Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the At-Risk and Earliest Phases of Rheumatoid Arthritis.

Rodríguez-Carrio J, Hähnlein JS, Ramwadhdoebe TH, Semmelink JF, Choi IY, van Lienden KP, Maas M, Gerlag DM, Tak PP, Geijtenbeek TB, van Baarsen LG.

Arthritis Rheumatol. 2017 Jan;69(1):70-76. doi: 10.1002/art.39811.

10.

Human lymph-node CD8(+) T cells display an altered phenotype during systemic autoimmunity.

Ramwadhdoebe TH, Hähnlein J, van Kuijk BJ, Choi IY, van Boven LJ, Gerlag DM, Tak PP, van Baarsen LG.

Clin Transl Immunology. 2016 Apr 1;5(4):e67. doi: 10.1038/cti.2016.8. eCollection 2016 Apr.

11.

Expression of Prostaglandin E2 Enzymes in the Synovium of Arthralgia Patients at Risk of Developing Rheumatoid Arthritis and in Early Arthritis Patients.

de Hair MJ, Leclerc P, Newsum EC, Maijer KI, van de Sande MG, Ramwadhdoebe TH, van Schaardenburg D, van Baarsen LG, Korotkova M, Gerlag DM, Tak PP, Jakobsson PJ.

PLoS One. 2015 Jul 30;10(7):e0133669. doi: 10.1371/journal.pone.0133669. eCollection 2015.

12.

Tertiary Lymphoid Structures in Rheumatoid Arthritis: NF-κB-Inducing Kinase-Positive Endothelial Cells as Central Players.

Noort AR, van Zoest KP, van Baarsen LG, Maracle CX, Helder B, Papazian N, Romera-Hernandez M, Tak PP, Cupedo T, Tas SW.

Am J Pathol. 2015 Jul;185(7):1935-43. doi: 10.1016/j.ajpath.2015.03.012. Epub 2015 May 9.

13.

Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression.

Angiolilli C, Grabiec AM, Ferguson BS, Ospelt C, Malvar Fernandez B, van Es IE, van Baarsen LG, Gay S, McKinsey TA, Tak PP, Baeten DL, Reedquist KA.

Ann Rheum Dis. 2016 Feb;75(2):430-8. doi: 10.1136/annrheumdis-2014-205635. Epub 2014 Dec 1.

14.

Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?

van Baarsen LG, Lebre MC, van der Coelen D, Aarrass S, Tang MW, Ramwadhdoebe TH, Gerlag DM, Tak PP.

Arthritis Res Ther. 2014 Aug 22;16(4):426. doi: 10.1186/s13075-014-0426-z.

15.

JNK-dependent downregulation of FoxO1 is required to promote the survival of fibroblast-like synoviocytes in rheumatoid arthritis.

Grabiec AM, Angiolilli C, Hartkamp LM, van Baarsen LG, Tak PP, Reedquist KA.

Ann Rheum Dis. 2015 Sep;74(9):1763-71. doi: 10.1136/annrheumdis-2013-203610. Epub 2014 May 8.

PMID:
24812285
16.

Gene expression analysis in RA: towards personalized medicine.

Burska AN, Roget K, Blits M, Soto Gomez L, van de Loo F, Hazelwood LD, Verweij CL, Rowe A, Goulielmos GN, van Baarsen LG, Ponchel F.

Pharmacogenomics J. 2014 Apr;14(2):93-106. doi: 10.1038/tpj.2013.48. Epub 2014 Mar 4. Review.

17.

Reply: To PMID 24574210.

de Hair MJ, van de Sande MG, Ramwadhdoebe TH, van der Leij C, Maas M, Hansson M, Klareskog L, Landewé R, Serre G, van Schaardenburg D, Gerlag DM, van Baarsen LG, Tak PP.

Arthritis Rheumatol. 2014 Jun;66(6):1683-4. doi: 10.1002/art.38411. No abstract available.

18.

Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis.

de Hair MJ, van de Sande MG, Ramwadhdoebe TH, Hansson M, Landewé R, van der Leij C, Maas M, Serre G, van Schaardenburg D, Klareskog L, Gerlag DM, van Baarsen LG, Tak PP.

Arthritis Rheumatol. 2014 Mar;66(3):513-22. doi: 10.1002/art.38273.

19.

The cellular composition of lymph nodes in the earliest phase of inflammatory arthritis.

van Baarsen LG, de Hair MJ, Ramwadhdoebe TH, Zijlstra IJ, Maas M, Gerlag DM, Tak PP.

Ann Rheum Dis. 2013 Aug;72(8):1420-4. doi: 10.1136/annrheumdis-2012-202990. Epub 2013 May 9.

20.

Smoking and overweight determine the likelihood of developing rheumatoid arthritis.

de Hair MJ, Landewé RB, van de Sande MG, van Schaardenburg D, van Baarsen LG, Gerlag DM, Tak PP.

Ann Rheum Dis. 2013 Oct;72(10):1654-8. doi: 10.1136/annrheumdis-2012-202254. Epub 2012 Oct 27.

21.

EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis.

Gerlag DM, Raza K, van Baarsen LG, Brouwer E, Buckley CD, Burmester GR, Gabay C, Catrina AI, Cope AP, Cornelis F, Dahlqvist SR, Emery P, Eyre S, Finckh A, Gay S, Hazes JM, van der Helm-van Mil A, Huizinga TW, Klareskog L, Kvien TK, Lewis C, Machold KP, Rönnelid J, van Schaardenburg D, Schett G, Smolen JS, Thomas S, Worthington J, Tak PP.

Ann Rheum Dis. 2012 May;71(5):638-41. doi: 10.1136/annrheumdis-2011-200990. Epub 2012 Mar 2.

22.

[Tailored therapy for rheumatic disease within reach].

van Baarsen LG, Lodde BM, Tak PP.

Ned Tijdschr Geneeskd. 2011;155(30-31):A3569. Dutch.

PMID:
22085519
23.

Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets.

de Launay D, van de Sande MG, de Hair MJ, Grabiec AM, van de Sande GP, Lehmann KA, Wijbrandts CA, van Baarsen LG, Gerlag DM, Tak PP, Reedquist KA.

Ann Rheum Dis. 2012 Mar;71(3):415-23. doi: 10.1136/ard.2010.143529. Epub 2011 Sep 27.

24.

Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritis.

Corr M, Boyle DL, Ronacher LM, Lew BR, van Baarsen LG, Tak PP, Firestein GS.

Ann Rheum Dis. 2011 May;70(5):858-63. doi: 10.1136/ard.2010.141077. Epub 2011 Jan 7.

25.

Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials.

van de Sande MG, Gerlag DM, Lodde BM, van Baarsen LG, Alivernini S, Codullo V, Felea I, Vieira-Sousa E, Fearon U, Reece R, Montecucco C, Veale DJ, Pitzalis C, Emery P, Klareskog L, McInnes IB, Tak PP.

Ann Rheum Dis. 2011 Mar;70(3):423-7. doi: 10.1136/ard.2010.139550. Epub 2010 Nov 24.

PMID:
21109518
26.

Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance.

Cantaert T, Baeten D, Tak PP, van Baarsen LG.

Arthritis Res Ther. 2010;12(5):219. doi: 10.1186/ar3150. Epub 2010 Oct 28. Review.

27.

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.

Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, van Baarsen LG, Bos C, Kirou KA, Gerlag DM, Crow MK, Bijlsma JW, Verweij CL, Tak PP.

Arthritis Rheum. 2010 Dec;62(12):3607-14. doi: 10.1002/art.27702.

28.

The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis.

Lindberg J, Wijbrandts CA, van Baarsen LG, Nader G, Klareskog L, Catrina A, Thurlings R, Vervoordeldonk M, Lundeberg J, Tak PP.

PLoS One. 2010 Jun 25;5(6):e11310. doi: 10.1371/journal.pone.0011310.

29.

Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis.

van Baarsen LG, Wijbrandts CA, Gerlag DM, Rustenburg F, van der Pouw Kraan TC, Dijkmans BA, Tak PP, Verweij CL.

Genes Immun. 2010 Dec;11(8):622-9. doi: 10.1038/gene.2010.34. Epub 2010 Jun 17.

PMID:
20555356
30.

Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood.

van Baarsen LG, Wijbrandts CA, Timmer TC, van der Pouw Kraan TC, Tak PP, Verweij CL.

Arthritis Rheum. 2010 Jun;62(6):1602-7. doi: 10.1002/art.27415.

31.

Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis.

van Baarsen LG, Bos WH, Rustenburg F, van der Pouw Kraan TC, Wolbink GJ, Dijkmans BA, van Schaardenburg D, Verweij CL.

Arthritis Rheum. 2010 Mar;62(3):694-704. doi: 10.1002/art.27294.

32.

Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment.

van Baarsen LG, Wijbrandts CA, Rustenburg F, Cantaert T, van der Pouw Kraan TC, Baeten DL, Dijkmans BA, Tak PP, Verweij CL.

Arthritis Res Ther. 2010;12(1):R11. doi: 10.1186/ar2912. Epub 2010 Jan 22.

33.

Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.

Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, van der Pouw Kraan TC, Verweij CL, Tak PP, Baeten DL.

Rheumatology (Oxford). 2010 Jan;49(1):156-66. doi: 10.1093/rheumatology/kep345. Epub 2009 Nov 23. Erratum in: Rheumatology (Oxford). 2014 Apr;53(4):770. van der Pouw, Tineke Kraan [corrected to van der Pouw Kraan, Tineke C T M].

PMID:
19933783
34.

Transcription profiling of rheumatic diseases.

van Baarsen LG, Bos CL, van der Pouw Kraan TC, Verweij CL.

Arthritis Res Ther. 2009;11(1):207. doi: 10.1186/ar2557. Epub 2009 Jan 30. Review.

35.

Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers.

Bos CL, van Baarsen LG, Timmer TC, Overbeek MJ, Basoski NM, Rustenburg F, Baggen JM, Thiesen HJ, Dijkmans BA, van der Pouw Kraan TC, Voskuyl AE, Verweij CL.

Genes Immun. 2009 Apr;10(3):210-8. doi: 10.1038/gene.2008.98. Epub 2009 Jan 8.

PMID:
19129850
36.

Pharmacogenomics of IFN-beta in multiple sclerosis: towards a personalized medicine approach.

Vosslamber S, van Baarsen LG, Verweij CL.

Pharmacogenomics. 2009 Jan;10(1):97-108. doi: 10.2217/14622416.10.1.97. Review.

PMID:
19102719
37.

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.

van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J, van der Pouw Kraan TC, Polman CH, Verweij CL.

PLoS One. 2008 Apr 2;3(4):e1927. doi: 10.1371/journal.pone.0001927.

38.

Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.

van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.

Ann Rheum Dis. 2008 Apr;67(4):563-6. Epub 2007 Nov 27.

PMID:
18042642
39.

Gene expression profiling in rheumatology.

van der Pouw Kraan TC, van Baarsen LG, Rustenburg F, Baltus B, Fero M, Verweij CL.

Methods Mol Med. 2007;136:305-27.

PMID:
17983157
40.

Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients.

van der Pouw Kraan TC, van Baarsen LG, Wijbrandts CA, Voskuyl AE, Rustenburg F, Baggen JM, Dijkmans BA, Tak PP, Verweij CL.

Genes Immun. 2008 Jan;9(1):16-22. Epub 2007 Oct 11.

PMID:
17928867
41.

Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.

van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, Ibrahim SM, Fero M, Dijkmans BA, Tak PP, Verweij CL.

Ann Rheum Dis. 2007 Aug;66(8):1008-14. Epub 2007 Jan 12.

42.

A subtype of multiple sclerosis defined by an activated immune defense program.

van Baarsen LG, van der Pouw Kraan TC, Kragt JJ, Baggen JM, Rustenburg F, Hooper T, Meilof JF, Fero MJ, Dijkstra CD, Polman CH, Verweij CL.

Genes Immun. 2006 Sep;7(6):522-31. Epub 2006 Jul 13.

PMID:
16837931
43.

Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis.

Kasperkovitz PV, Timmer TC, Smeets TJ, Verbeet NL, Tak PP, van Baarsen LG, Baltus B, Huizinga TW, Pieterman E, Fero M, Firestein GS, van der Pouw Kraan TC, Verweij CL.

Arthritis Rheum. 2005 Feb;52(2):430-41.

Supplemental Content

Loading ...
Support Center